Efficacy and safety of meropenem (3 g daily) in Japanese patients with refractory respiratory infections

Kawanami, Toshinori; Mukae, Hiroshi; Noguchi, Shingo; Yamasaki, Kei; Akata, Kentaro; Ishimoto, Hiroshi; Matsumoto, Kana; Morita, Kunihiko; Yatera, Kazuhiro

doi:10.1016/j.jiac.2014.08.011

Cited by 10 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Meropenem was administered intravenously at the daily dose of 3 grams to patients with lower respiratory-tract infection. Following the intravenous dose of 1 gram of meropenem the plasma concentration of meropenem is 44.9±12.0 µg/ml and the MIC of the organisms causing the infection ranges from 4 to 8 µg/ml thus this treatment effectively and safely cures the patients [3]. Patients with urinary-tract infection received meropenem intravenously at the dose of 0.5 grams thrice-daily and patients with lower respiratory-tract infection received meropenem intravenously at the dose of 1 gram thrice-daily.…”

Section: Discussionmentioning

confidence: 99%

“…The plasma concentration of meropenem one hour after the administration of 1 gram of meropenem was 44.9±12.0 µg/ml. The minimum inhibitory concentration (MIC) of the organisms causing the infection ranged from 4 to 8 µg/ml thus this treatment effectively and safely cured the patients with lower respiratory-tract infection [3]. One-hundred-fifty-three patients were enrolled, 45 patients (29.4%) had urinary-tract and 108 patients (70.6%) had lower respiratory-tract infection.…”

Section: Efficacy and Safely Of Meropenemmentioning

confidence: 99%

See 1 more Smart Citation

Clinical Pharmacology of Meropenem

Pacifici

2024

BJSTR

View full text Add to dashboard Cite

Meropenem is a carbapenem antibiotic and has a broader spectrum of activity than most β-lactam antibiotics, does not require co-administration with cilastatin because is not sensitive to renal dipeptidase, is available for intravenous infusion, is renally cleared, and the dose of meropenem is 1 or 2 grams thrice-daily. The efficacy and safely of meropenem, the prophylaxis with meropenem, the treatment of bacterial infections with meropenem, and the trials conducted with meropenem have been reviewed. The pharmacokinetics of meropenem have been studied in patients with serve sepsis or with septic shock and in healthy subjects and the mean elimination half-life of meropenem is 3.30 and 0.61 hours (P-value < 0.05) in patients and in healthy subjects, respectively. The concentration of meropenem in human tissues has been reviewed; meropenem poorly penetrates into the brain whereas it penetrates into lung, bronchial mucosa, and pleural tissue in concentration higher the MIC of most respiratory pathogens. The penetration of meropenem into the human cerebrospinal fluid has been reviewed and meropenem poorly penetrates into the cerebrospinal fluid. The median elimination half-life of meropenem is 0.63 and 13.86 hours in the serum and in the cerebrospinal fluid, respectively, and the median absorption half-life of meropenem is 23.10 hours in cerebrospinal fluid. Meropenem successfully treats bacterial meningitis and significantly reduces the serum concentration of valproic acid. The aim of this study is to review meropenem efficacy and safely, prophylaxis, treatment, trials, pharmacokinetics, tissue and cerebrospinal fluid concentration, treatment of bacterial meningitis, and interaction with valproic acid.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Efficacy and Safely Of Meropenemmentioning

confidence: 99%

Clinical Pharmacology of Meropenem

Pacifici

2024

BJSTR

View full text Add to dashboard Cite

show abstract

“…In our patient, DRPM (1.5 g/day) was ineffective, but the increased dose of 3.0 g/day was effective. Carbapenem antibiotics require ≥50% time above minimum inhibitory concentration (% TAM) to achieve the maximum bactericidal effect, and the plasma concentration of MEPM clearly increased after increasing the dose of MEPM from 1.5 g/day to 3.0 g/day (33). Thus, an increase in the antibiotic dose can be effective when the clinical response to a medium dose of carbapenem is poor.…”

Section: Discussionmentioning

confidence: 99%

Pulmonary Nocardiosis Caused by <i>Nocardia exalbida</i> in a Patient with Lung Cancer and Radiation Pneumonitis: A Case Report and Literature Review

et al. 2019

Self Cite

View full text Add to dashboard Cite

We report a case of Nocardia exalbida ( N. exalbida )-induced pneumonia in a 70-year old Japanese man with lung cancer and radiation pneumonitis. He initially received doripenem (1.5 g/day) for pneumonia treatment, and N. exalbida was identified by a clone library analysis of bronchoalveolar lavage fluid obtained from the pneumonia lesion. The doripenem dosage was therefore increased to 3.0 g/day with adjunctive trimethoprim/sulfamethoxazole, and his pneumonia improved. N. exalbida is susceptible to antibiotics; thus, in nocardiosis, N. exalbida infection might be associated with a good response to treatment, although its clinical findings are non-specific and similar to those of other Nocardia infections.

show abstract